We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Iconic Labs Plc | LSE:ICON | London | Ordinary Share | GB00BRBJ3P08 | ORD GBP0.0001 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 5.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Health & Allied Services,nec | 0 | 4.77M | 0.5697 | 0.09 | 418.58k |
TIDMICON
RNS Number : 1540M
Iconic Labs PLC
12 September 2023
12 September 2023
Iconic Labs PLC
("Iconic" or the "Company")
Allotment of Shares and Conclusion of CVA
Iconic Labs PLC (LSE: ICON) today announces that 83,256 ordinary shares of GBP0.1 were allotted to the unsecured creditors (the "Unsecured Creditors") in accordance with the Creditors Voluntary Arrangement (CVA) dated 22 September 2022.
Application is being made for 83,256 new Ordinary Shares to be admitted to trading on the Main Market of the London Stock Exchange which is expected to be on or around 15 September 2023. These shares rank pari passu with the existing Ordinary Shares of the Company.
Following the issue of these shares, the Company's issued ordinary share capital shall consist of 5,003,275 Ordinary Shares. The figure of 5,003,275 represents the total voting rights in the Company and should be used by shareholders as the denominator for the calculation by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance & Transparency Rules.
Brad Taylor, Chief Executive Officer of Iconic Labs, commented:
"We are pleased to announce the allotment of shares to the Unsecured Creditors satisfies the final condition to bring the CVA to a successful conclusion. Once the CVA is discharged, Iconic will be well positioned to focus on its business goals. The Board remains committed to delivering value to our shareholders and stakeholders alike. "
- Ends -
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.
For any further information or enquiries please contact:
Iconic Labs Tel: +44 (0) 7462 156238 Brad Taylor, Chief Executive ir@iconiclabs.co.uk Officer Novum Securities Limited Tel: +44 (0) 20 7399 9400 David Coffman / Daniel Harris Yellow Jersey PR Tel: +44 (0) 20 3004 9512 Sarah Hollins iconic@yellowjerseypr.com Annabelle Wills Bessie Elliot
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
STRUUSBRORUKARR
(END) Dow Jones Newswires
September 12, 2023 03:45 ET (07:45 GMT)
1 Year Iconic Labs Chart |
1 Month Iconic Labs Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions